Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis
Meta-analysis shows PSA nadir predicts better outcomes in patients treated with ARPI or docetaxel in metastatic hormone-sensitive prostate cancer.
Key Points
The study aims to determine the prognostic significance of PSA nadir levels in metastatic hormone-sensitive prostate cancer treated with ARPI or docetaxel.
Conducted a reconstructed individual patient data meta-analysis.
Included 8 studies with data on mHSPC patients receiving first-line ARPI or docetaxel.
Analyzed overall survival and progression-free survival based on PSA nadir levels.
Patients with PSA nadir ≤ 0.2 had better median OS of 92.8 months compared to 34 months for PSA nadir > 0.2 (HR 0.27, 95% CI 0.22-0.33, p < 0.0001).
Median PFS was not reached for PSA nadir ≤ 0.2 versus 12.1 months for > 0.2 (HR 0.19, 95% CI 0.16-0.23, p < 0.0001).